BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8994301)

  • 1. The contribution of the mouse in hazard identification studies.
    Maronpot RR; Boorman GA
    Toxicol Pathol; 1996; 24(6):726-31. PubMed ID: 8994301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides.
    Billington R; Lewis RW; Mehta JM; Dewhurst I
    Crit Rev Toxicol; 2010 Jan; 40(1):35-49. PubMed ID: 20144135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternatives to the 2-species bioassay for the identification of potential human carcinogens.
    Ashby J
    Hum Exp Toxicol; 1996 Mar; 15(3):183-202. PubMed ID: 8839204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009).
    Friedrich A; Olejniczak K
    Regul Toxicol Pharmacol; 2011 Jul; 60(2):225-48. PubMed ID: 21513764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.
    Contrera JF; DeGeorge JJ
    Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):71-80. PubMed ID: 9539006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals.
    Contrera JF; Jacobs AC; DeGeorge JJ
    Regul Toxicol Pharmacol; 1997 Apr; 25(2):130-45. PubMed ID: 9185889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A perspective on current and future uses of alternative models for carcinogenicity testing.
    Goodman JI
    Toxicol Pathol; 2001; 29 Suppl():173-6. PubMed ID: 11695554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and intermediate-term carcinogenicity testing--a review. Part 1: the prototypes mouse skin tumour assay and rat liver focus assay.
    Enzmann H; Bomhard E; Iatropoulos M; Ahr HJ; Schlueter G; Williams GM
    Food Chem Toxicol; 1998 Nov; 36(11):979-95. PubMed ID: 9771562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for the evaluation of chemicals for carcinogenicity. Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment.
    Rep Health Soc Subj (Lond); 1991; 42():1-80. PubMed ID: 1763238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
    Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles.
    Kirkland D; Aardema M; Müller L; Makoto H
    Mutat Res; 2006 Sep; 608(1):29-42. PubMed ID: 16769241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Tg rasH2 mouse in cancer hazard identification.
    Morton D; Alden CL; Roth AJ; Usui T
    Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the utility of the lifetime mouse bioassay in the identification of cancer hazards for humans.
    Osimitz TG; Droege W; Boobis AR; Lake BG
    Food Chem Toxicol; 2013 Oct; 60():550-62. PubMed ID: 23954551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2-year rodent bioassay in drug and chemical carcinogenicity testing: Performance, utility, and configuration for cancer hazard identification.
    Suarez-Torres JD; Orozco CA; Ciangherotti CE
    J Pharmacol Toxicol Methods; 2021; 110():107070. PubMed ID: 33905862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical appraisal of the value of the mouse cancer bioassay in safety assessment.
    Alden CL; Smith PF; Piper CE; Brej L
    Toxicol Pathol; 1996; 24(6):722-5. PubMed ID: 8994300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vivo rodent test systems for assessment of carcinogenic potential.
    van der Laan JW; Spindler P
    Regul Toxicol Pharmacol; 2002 Feb; 35(1):122-5. PubMed ID: 11846641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances.
    Jacobs MN; Colacci A; Louekari K; Luijten M; Hakkert BC; Paparella M; Vasseur P
    ALTEX; 2016; 33(4):359-392. PubMed ID: 27120445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of carcinogenicity from two versus four sex-species groups in the carcinogenic potency database.
    Gold LS; Slone TH
    J Toxicol Environ Health; 1993 May; 39(1):143-57. PubMed ID: 8492327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.